WEATHER ALERT January 27, 2026 (12:00 PM): Due to the recent inclement weather, we are experiencing higher than usual call volume. Your call is important to us. We strongly recommend current patients utilize the Patient Portal to reach their clinical teams with questions or to adjust their appointment if necessary. Messages received in the Patient Portal will be returned as quickly as possible. Thank you for your patience.
A radioconjugate composed of an optimized affibody conjugated, via its C-terminal cysteine, to maleimide-DOTA, and linked to the radioisotope gallium Ga 68, with potential use as a tracer for human epidermal growth factor receptor type 2 (HER2; ErbB2)-expressing tumors using positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68-labeled affibody ABY-025, the affibody targets HER2-expressing tumor cells. This facilitates both detection of HER2-expressing tumor cells and assessment of responses to HER2-targeting chemotherapeutic agents during PET imaging. The affibody is an optimized antibody mimetic based on a 6.5-kDa 3-helical bundle Z domain derived from the staphylococcal protein A (Z her2:342); the nonbinding surface of the Z domain is reengineered (Z her2:2891) to increase binding affinity for HER2 and to improve tumor imaging. HER2 is overexpressed in many cancer cell types. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
